Is IPCIF or ORCC a better dividend investment in 2026?

IPCIF currently yields 1333.33% with a 5% 5-year dividend growth rate. ORCC yields 9.79% with 5% growth. The better choice depends on your goal: IPCIF offers higher current income.

What is the dividend yield difference between IPCIF and ORCC?

IPCIF has a forward dividend yield of 1333.33% ($2.00/share annually). ORCC yields 9.79% ($1.32/share annually). The yield gap is 1323.54 percentage points.

Home › Compare › IPCIF vs ORCC

IPCIF vs ORCC: Dividend Comparison 2026

IPCIF yields 1333.33% · ORCC yields 9.79%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 IPCIF wins by $241528700.59M in total portfolio value

INVESTMENT

TIME HORIZON10 years

IPCIF

● Live price

1333.33%

Share price

$0.15

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$241528700.61M

Annual income

$210,475,860,072,406.56

Full IPCIF calculator →

ORCC

● Live price

9.79%

Share price

$13.48

Annual div

$1.32

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$21.4K

Annual income

$1.04

Full ORCC calculator →

Portfolio growth — IPCIF vs ORCC

📍 IPCIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	IPCIF	ORCC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, IPCIF + ORCC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

IPCIF pays

ORCC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPCIF

Annual income on $10K today (after 15% tax)

$113,333.33/yr

After 10yr DRIP, annual income (after tax)

$178,904,481,061,545.56/yr

ORCC

Annual income on $10K today (after 15% tax)

$832.34/yr

After 10yr DRIP, annual income (after tax)

$0.88/yr

At 15% tax rate, IPCIF beats the other by $178,904,481,061,544.70/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPCIF + ORCC for your $10,000?

IPCIF: 50%ORCC: 50%

100% ORCC50/50100% IPCIF

Portfolio after 10yr

$120764350.32M

Annual income

$105,237,930,036,203.80/yr

Blended yield

87.14%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

IPCIF

No analyst data

Altman Z

-111.3

Piotroski

4/9

ORCC

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$16.00

+18.7% upside vs current

Range: $16.00 — $16.00

Altman Z

0.5

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPCIF buys

ORCC buys

No recent congressional trades found for IPCIF or ORCC in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricIPCIFORCC

Forward yield	1333.33% ✓	9.79%
Annual dividend / share	$2.00 ✓	$1.32
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0% ✓	-50%
Portfolio after 10y	$241528700.61M ✓	$21.4K
Annual income after 10y	$210,475,860,072,406.56 ✓	$1.04
Total dividends collected	$239239876.27M ✓	$1.0K
Payment frequency	quarterly	quarterly
Sector	Stock	BDC

Year-by-year: IPCIF vs ORCC ($10,000, DRIP)

Year	IPCIF Portfolio	IPCIF Income/yr	ORCC Portfolio	ORCC Income/yr	Gap
1← crossover	$144,033	$133,333.33	$11,190	$489.61	+$132.8K → IPCIF
2	$1,948,924	$1,794,807.89	$12,229	$256.01	+$1.94M → IPCIF
3	$24,782,219	$22,696,870.86	$13,216	$130.74	+$24.77M → IPCIF
4	$296,245,945	$269,728,970.81	$14,207	$66.02	+$296.23M → IPCIF
5	$3,330,378,004	$3,013,394,842.54	$15,234	$33.17	+$3330.36M → IPCIF
6	$35,223,684,321	$31,660,179,856.69	$16,317	$16.62	+$35223.67M → IPCIF
7	$350,636,384,108	$312,947,041,885.16	$17,468	$8.32	+$350636.37M → IPCIF
8	$3,286,630,500,315	$2,911,449,569,318.85	$18,695	$4.16	+$3286630.48M → IPCIF
9	$29,021,346,295,663	$25,504,651,660,325.88	$20,006	$2.08	+$29021346.28M → IPCIF
10	$241,528,700,608,766	$210,475,860,072,406.56	$21,407	$1.04	+$241528700.59M → IPCIF

IPCIF vs ORCC: Complete Analysis 2026

IPCIF — Stock

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Full IPCIF Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →

📬

Get this IPCIF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPCIF vs SCHD IPCIF vs JEPI IPCIF vs O IPCIF vs KO IPCIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.